Advanced Filter

Filter by Group

Filter by Market Availability

Displaying drugs 376 - 400 of 11364 in total
Ethanolamine oleate is a mild sclerosing agent. It is composed of ethanolamine, a basic substance, which when combined with oleic acid forms a clear, straw to pale yellow colored, deliquescent oleate.
Approved
Matched Description: … It is composed of ethanolamine, a basic substance, which when combined with oleic acid forms a clear, ... Ethanolamine oleate is a mild sclerosing agent. …
Matched Categories: … Compounds used in a research, industrial, or household setting …
Tacrolimus (also FK-506 or Fujimycin) is an immunosuppressive drug whose main use is after organ transplant to reduce the activity of the patient's immune system and so the risk of organ rejection. It is also used in a topical preparation in the treatment of severe atopic dermatitis, severe refractory uveitis...
Approved
Investigational
Matched Description: … Tacrolimus is chemically known as a macrolide. ... It is also used in a topical preparation in the treatment of severe atopic dermatitis, severe refractory ... It was discovered in 1984 from the fermentation broth of a Japanese soil sample that contained the bacteria …
Matched Categories: … P-glycoprotein substrates with a Narrow Therapeutic Index ... Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic Index ... Cytochrome P-450 CYP3A5 Substrates with a Narrow Therapeutic Index …
Sunitinib is a small-molecule multi-targeted receptor tyrosine kinase (RTK) inhibitor. On January 26, 2006, the agent was formally approved by the US FDA for the indications of treating renal cell carcinoma (RCC) and imatinib-resistant gastrointestinal stromal tumor (GIST). For these purposes, sunitinib is generally available as an orally administered formulation....
Approved
Investigational
Matched Description: … Sunitinib is a small-molecule multi-targeted receptor tyrosine kinase (RTK) inhibitor. …
Matched Categories: … Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic Index ... Cytochrome P-450 CYP3A5 Substrates with a Narrow Therapeutic Index ... Cytochrome P-450 CYP3A7 Substrates with a Narrow Therapeutic Index …
Articaine is a dental local anesthetic. Articaine is widely used around the world and is the most popular local anesthetic in many European countries.
Approved
Matched Description: … Articaine is a dental local anesthetic. …
Benign prostatic hyperplasia (BPH) refers to a benign growth or hyperplasia of the prostate and leads to lower urinary tract symptoms in men, such as urgency, frequency and changes to urine flow. The prevalence of BPH is as high as 50%-60% for males in their 60's, and this prevalence increases...
Approved
Investigational
Matched Description: … Benign prostatic hyperplasia (BPH) refers to a benign growth or hyperplasia of the prostate and leads …
Dimethyltubocurarinium (INN) or metocurine (USAN), also known as dimethyltubocurarine, is a non-depolarizing muscle relaxant. Patients on chronic anticonvulsant drugs are relatively resistant to metocurine.
Approved
Matched Description: … Dimethyltubocurarinium (INN) or metocurine (USAN), also known as dimethyltubocurarine, is a non-depolarizing …
Initially approved by the FDA in 2013, memantine is an N-methyl-D-aspartate (NMDA) receptor antagonist used in the management of Alzheimer's Disease (AD). It is different from many other Alzheimer's Disease medications, as it works by a different mechanism than the cholinesterase enzyme inhibitors normally employed in the management of Alzheimer's...
Approved
Investigational
Matched Description: … with the objective of developing a cure or a disease-modifying therapy by the year 2025 [L5953, F4366 ... It is different from many other Alzheimer's Disease medications, as it works by a different mechanism ... In December 2013, the G8 dementia summit concluded that dementia should be considered a global priority …
Fluticasone is a synthetic glucocorticoid available as 2 esters, DB08906 and DB00588[F4355,F4358,F4361,F4364][FDA Label]. These drugs are available as inhalers, nasal, sprays, and topical treatments for various inflammatory indications[F4355,F4358,F4361,F4364][FDA Label]. DB00588 was first approved in 1990 and DB08906 was approved in 2007 .
Approved
Experimental
Matched Iupac: … carbonyl}-1,10-dihydroxy-2,9a,11a-trimethyl-1H,2H,3H,3aH,3bH,4H,5H,7H,9aH,9bH,10H,11H,11aH-cyclopenta[a] …
Matched Description: … Fluticasone is a synthetic glucocorticoid available as 2 esters, [DB08906] and [DB00588][F4355,F4358, …
Tyropanoic acid is a radiocontrast agent used in cholecystography, the X-ray diagnosis of gallstones under the trade names include Bilopaque, Lumopaque, Tyropaque, and Bilopac. The molecule contains three heavy iodine atoms which obstruct X-rays in the same way as the calcium in bones, which results in a visible image .
Approved
Matched Description: … Tyropanoic acid is a radiocontrast agent used in cholecystography, the X-ray diagnosis of gallstones ... heavy iodine atoms which obstruct X-rays in the same way as the calcium in bones, which results in a
Matched Categories: … Compounds used in a research, industrial, or household setting …
Methylparaben is used in allergenic testing.
Approved
Matched Categories: … Compounds used in a research, industrial, or household setting …
Golodirsen is a morpholino antisense oligomer designed to treat about 8% of patients with Duchenne Muscular Dystrophy (DMD). This is an X-linked condition leading to progressive muscle degeneration that begins in early childhood, rendering many patients wheelchair-bound by age 12. Often, patients succumb to this condition by age 30 or...
Approved
Matched Description: … a different genetic mutation. ... Golodirsen is a morpholino antisense oligomer designed to treat about 8% of patients with Duchenne Muscular ... [A188580,T756] A similar drug used in the treatment of other types of DMD is [eteplirsen], which targets …
Matched Categories: … Compounds used in a research, industrial, or household setting …
Tricyclic antidepressant similar to imipramine, but with more antihistaminic and sedative properties.
Approved
Matched Categories: … P-glycoprotein substrates with a Narrow Therapeutic Index ... Cytochrome P-450 CYP2C9 Substrates with a Narrow Therapeutic Index ... Cytochrome P-450 CYP2C19 Substrates with a Narrow Therapeutic Index ... Cytochrome P-450 CYP2D6 Substrates with a Narrow Therapeutic Index …
Indigotindisulfonic acid is a blue-colored dye with a variety of uses.[A32490,A32491,A32492,L2222] Its salt form, indigotindisulfonate sodium, is also known as indigo carmine, indigotine or FD&C Blue #2. This compound is an acid-base indicator and is used in the production of food colorants and pH tests. Indigotindisulfonic acid is used in...
Approved
Investigational
Matched Description: … Indigotindisulfonic acid is a blue-colored dye with a variety of uses. …
Matched Categories: … Compounds used in a research, industrial, or household setting …
Phloxine B (commonly known simply as phloxine, also known as D&C RED NO. 28) is a color additive which is used both as an inactive ingredient to provide color to products, or as a colorant in dental disclosing tablets. These tablets allow patients to visualise areas where more brushing and...
Approved
Matched Description: … Phloxine B (commonly known simply as phloxine, also known as D&C RED NO. 28) is a color additive which ... is used both as an inactive ingredient to provide color to products, or as a colorant in dental disclosing …
Matched Categories: … Compounds used in a research, industrial, or household setting …
Arbutamine, administered through a closed-loop, computer-controlled drug-delivery system, is indicated to elicit acute cardiovascular responses, similar to those produced by exercise, in order to aid in diagnosing the presence or absence of coronary artery disease in patients who cannot exercise adequately .
Approved
Matched Description: … Arbutamine, administered through a closed-loop, computer-controlled drug-delivery system, is indicated …
Matched Categories: … Compounds used in a research, industrial, or household setting …
Approved
Experimental
Avacincaptad pegol is an RNA aptamer covalently bound to a branched polyethylene glycol (PEG) molecule. It was developed to treat an advanced form of age-related macular degeneration (AMD) called geographic atrophy (GA). AMD is the leading cause of vision loss in developed countries for people over 50 years old, with...
Approved
Investigational
Matched Description: … Avacincaptad pegol is an RNA aptamer covalently bound to a branched polyethylene glycol (PEG) molecule ... ] AMD is the leading cause of vision loss in developed countries for people over 50 years old, with a
Hydroxocobalamin, also known as vitamin B12a and hydroxycobalamin, is an injectable form of vitamin B 12 that has been used therapeutically to treat vitamin B 12 deficiency. It is also used in cyanide poisoning, Leber's optic atrophy, and toxic amblyopia.
Approved
A cardioselective beta-adrenergic antagonist with little effect on the bronchial receptors. The drug has stabilizing and quinidine-like effects on cardiac rhythm as well as weak inherent sympathomimetic action.
Approved
Investigational
Matched Description: … A cardioselective beta-adrenergic antagonist with little effect on the bronchial receptors. …
Phentermine is a sympathomimetic amine anorectic agent and it was introduced in 1959 as part of an anti-obesity combination drug.[A174361, A174364] It is chemically related to amphetamine and it is commonly referred to as an atypical amphetamine. Phentermine has not been reported an addictive potential which allows this agent to...
Approved
Illicit
Matched Description: … Phentermine is a sympathomimetic amine anorectic agent and it was introduced in 1959 as part of an anti-obesity ... A174376, T403] Later on, phentermine was approved alone and in combination with topiramate in 2012 as a
Matched Categories: … Monoamine Oxidase A Inhibitors for interaction with Monoamine Oxidase A substrates …
Brigatinib, originally named AP26113, is a reversible dual inhibitor of anaplastic lymphoma kinase (ALK) and epidermal growth factor receptor (EGFR). It presents selectivity against the mutant forms of EGFR compared to the wild-type. It also exhibits selectivity against 9 different Crizotinib-resistant mutants of the EML4-ALK fusion gene, which is a...
Approved
Investigational
Matched Description: … Brigatinib, originally named AP26113, is a reversible dual inhibitor of anaplastic lymphoma kinase (ALK ... selectivity against 9 different Crizotinib-resistant mutants of the EML4-ALK fusion gene, which is a ... [A31313] Brigatinib was developed by Ariad Pharmaceuticals, a subsidiary of Takeda Pharmaceutical Company …
Matched Categories: … Cytochrome P-450 CYP2C8 Substrates with a Narrow Therapeutic Index ... Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic Index …
Clocortolone is a medium potency corticosteroid that is often used as a topical cream for the relief of inflammatory oand pruritic (itching) arising from steroid-responsive dermatoses of the scalp.
Approved
Matched Iupac: … hydroxy-1-(2-hydroxyacetyl)-2,9a,11a-trimethyl-1H,2H,3H,3aH,3bH,4H,5H,7H,9aH,9bH,10H,11H,11aH-cyclopenta[a] …
Matched Description: … Clocortolone is a medium potency corticosteroid that is often used as a topical cream for the relief …
Acromegaly is a disorder caused by excess growth hormone (GH), increasing the growth of body tissues and causing metabolic dysfunction. In most cases, it results from an anterior pituitary growth hormone-releasing tumor. Typically, the feet, hands, and face grow abnormally large; organomegaly and insulin resistance may also occur. Acromegaly is...
Approved
Investigational
Matched Description: … Acromegaly is a life-threatening disease requiring life-long management. ... Acromegaly is a disorder caused by excess growth hormone (GH), increasing the growth of body tissues ... [L14501] Octreotide is a long-acting drug with pharmacologic activities that mimic those of the natural …
Regorafenib is an orally-administered inhibitor of multiple kinases. It is used for the treatment of metastatic colorectal cancer, advanced gastrointestinal stromal tumours, and hepatocellular carcinoma. FDA approved on September 27, 2012. Approved use of Regorafenib was expanded to treat Hepatocellular Carcinoma in April 2017.
Approved
Matched Categories: … UGT1A9 Substrates with a Narrow Therapeutic Index ... P-glycoprotein substrates with a Narrow Therapeutic Index ... Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic Index …
Regadenoson is an A2A adenosine receptor agonist that causes coronary vasodilation and used for myocardial perfusion imagining. Manufactured by Astellas and FDA approved April 10, 2008.
Approved
Investigational
Matched Categories: … Adenosine A receptor agonists …
Displaying drugs 376 - 400 of 11364 in total